How Oxford Medical Sciences is fighting Coronavirus
Researchers from across the Medical Sciences Division are working hard to combat the COVID-19 crises. With particular strengths in infectious diseases and international health, we are well placed to contribute to better understanding and effectively controlling the epidemic. We have a long history of responding to crises, in the UK and around the world and are leaders in emergency vaccine development. During the 2014 Ebola outbreak, our scientists performed the world’s first human Ebola vaccine studies, starting them before any other university or company. Our researchers, in collaboration with partners across the globe, are working to develop an effective vaccine and drugs to target this virus, and have already introduced innovative public health measures and collaborative online tools that are being used in hospitals here and abroad.
Support our Research
Find out how to support Oxford's coronavirus work across a number of key research areas.
Support our researchers
Opportunities for our researchers and support requests.
Coronavirus-related news from across the Medical Sciences Division
Attention and memory deficits persist for months after recovery from mild Covid
19 January 2022
Researchers from Oxford’s Department of Experimental Psychology and Nuffield Department of Clinical Neurosciences have shown that people who have had Covid but don’t complain of long Covid symptoms in daily life nevertheless can show degraded attention and memory for up to 6-9 months.
Dramatic fall in hospital admissions for child infections since start of Covid-19 pandemic
13 January 2022
Since the onset of the Covid-19 pandemic, there have been dramatic reductions in hospital admissions for common and severe childhood infections in England, most likely due to social distancing measures, school and workplace closures, and travel restrictions, finds a study published by The BMJ today.
Oxford team publish blueprint for making millions of doses of a new vaccine within 100 days
22 December 2021
The University of Oxford’s vaccine manufacturing research team has today published a pre-print paper demonstrating the feasibility of a step change in the speed and volume of production of adenovirus-vectored vaccines against new virus variants or other future pandemics.
Research finds drug may benefit some patients hospitalised with COVID-19 pneumonia
17 December 2021
A proof-of-concept trial involving Oxford researchers has identified a drug that may benefit some patients hospitalised with COVID-19 pneumonia.
Many Long COVID patients continue to experience symptoms one year after hospital discharge
16 December 2021
People who were hospitalised with COVID-19 and continued to experience symptoms five months later, show limited further recovery one year after hospital discharge according to the latest results of a major national study.
Vaccines shown to induce lower levels of neutralising antibodies against Omicron coronavirus variant
13 December 2021
Researchers from the University of Oxford have analysed the impact of the Omicron COVID-19 variant of concern on one of the immune responses generated by vaccination.
RECOVERY Trial launches in South Africa
13 December 2021
The world’s largest clinical trial investigating treatments for COVID-19 has now launched in South Africa, with the first patient recruited today. This is the fifth country to take part in RECOVERY, joining Nepal, Indonesia, Vietnam, and the United Kingdom.
Professor Dame Sarah Gilbert delivers 44th Dimbleby Lecture
7 December 2021
Professor Dame Sarah Gilbert, Saïd Professorship of Vaccinology, Jenner Institute & Nuffield Department of Clinical Medicine, delivered the 44th Richard Dimbleby Lecture, named after the late broadcaster, Richard Dimbleby.
Com-COV2 study supports flexible second dose options following Pfizer or Oxford/AstraZeneca jabs
7 December 2021
Following up first doses of the Oxford-AstraZeneca or Pfizer-BioNTech vaccines with second doses of the Moderna or Novavax jabs will generate robust immune responses against COVID-19, according to researchers running the University of Oxford-led Com-COV study.
Oxford researchers honoured by British Society for Immunology
3 December 2021
Four researchers from the University of Oxford have been recognised for their outstanding contributions to immunology with Honorary Lifetime Membership of the British Society for Immunology, with the awards being announced at the recent British Society for Immunology Congress held in Edinburgh.
Find out how other parts of the University are tackling COVID-19
Researchers across the University of Oxford are at the forefront of global efforts to understand COVID-19 and protect our communities.
Support our Research
Find out how to support Oxford's coronavirus work across a number of key research areas.